Xenon Pharmaceuticals Inc. (NASDAQ:XENE) advanced its epilepsy program while encountering a new obstacle to expansion. On September 17, it submitted a New Drug Application to the U.S. Food and Drug Administration for azetukalner in focal seizures, which originate in a specific area of the brain.
The same announcement disclosed a voluntary pause in new enrollment in ongoing major depressive disorder and bipolar depression studies following analysis of neuropsychiatric adverse events. Existing participants remain on study, including those in associated open-label extensions, and ongoing epilepsy trials continue. Management expects the pause to be temporary.
For investors, these developments require separate judgments. The epilepsy application advances a potential first commercial product, while the psychiatric program must establish that the same drug can deliver an acceptable balance of benefit and tolerability in different patients.
Bull Case
Xenon Pharmaceuticals Inc. has substantial clinical evidence behind the epilepsy filing. The application draws on the randomized, double-blind, placebo-controlled Phase 2b X-TOLE and Phase 3 X-TOLE2 studies, with more than 1,500 patient-years of safety exposure across the epilepsy program.
In X-TOLE2, median monthly focal-seizure frequency fell 53.2% from baseline with the 25 mg dose and 34.5% with 15 mg, compared with 10.4% for placebo over the 12-week treatment period. Both active doses met the primary endpoint with statistically significant results. Those findings support the seizure-treatment opportunity independently of success in depression.
The psychiatric program also retains a near-term opportunity to produce evidence. Xenon Pharmaceuticals Inc. will complete X-NOVA2 with approximately 360 patients, versus its original target of 450, and expects topline results in the first quarter of 2027.
Management says the reduced enrollment remains sufficient to detect a clinically meaningful change on the primary endpoint, the HAM-D17 depression-severity scale. Participants will finish the six-week dosing period before the data are unblinded. Potential dosing changes could preserve a path forward if they improve tolerability while retaining antidepressant activity.
Bear Case
The pause exposes uncertainty in the proposed expansion beyond seizures. Xenon Pharmaceuticals Inc. says the events, their frequency and severity, are consistent with azetukalner’s known safety profile, but such events had not appeared in the earlier Phase 2 depression study. Although the release omitted specifics, management later described confusion, speech and coordination difficulties, and a small number of events categorized as psychosis, according to Reuters.
Epilepsy data also show a dose-related tolerability trade-off. In X-TOLE2, treatment-emergent adverse events led to discontinuation in 14.5% of the 25 mg group, 4.8% of the 15 mg group and 3.2% of placebo recipients. These are epilepsy-study figures, not rates from the paused psychiatric studies.
Changing the psychiatric dosing regimen could require additional testing and extend development spending. Better tolerability would have to come with preserved efficacy. The company’s assessment of statistical power also does not guarantee that the smaller X-NOVA2 trial will succeed or adequately characterize less common adverse events.
The epilepsy application remains subject to FDA review. Submission establishes neither acceptance for review nor approval, and continued trial enrollment does not resolve the psychiatric safety questions.
Hedge Fund Sentiment
The filings available so far reflect positions held before Xenon Pharmaceuticals Inc. reported its epilepsy application and psychiatry enrollment pause. Insider Monkey’s database showed 62 hedge funds holding Xenon Pharmaceuticals Inc. at the end of 2Q2026, down from 63 funds three months earlier.
Conclusion
Xenon Pharmaceuticals Inc. has a credible epilepsy development case, while expansion into depression remains uncertain. Detailed adverse-event disclosures, workable dosing changes, and the first-quarter 2027 X-NOVA2 results will determine whether psychiatric uses can add value. The key test is meaningful symptom improvement alongside tolerability that supports continued treatment.
READ NEXT: Korn Ferry (KFY) Grew Contracted Fees 14%. Can AMS Add Growth Without Squeezing Margins? and Mastercard (MA) Partners With Flowcart. Can In-Chat Payments Deliver Profitable Growth?
This article is originally published at Insider Monkey.
